Psychedelic Stocks & Companies
Looking to invest in companies at the forefront of psychedelic research, development, and production? This page serves as a director of public psychedelics companies and stocks (or ‘shroom stocks’), and private companies working in the space.
Public Psychedelics Companies
There are a growing number of psychedelics companies that are actively researching and developing psychedelics for medical and therapeutic purposes. Below is a directory of these psychedelic stocks, in no particular order. Where possible, we have offered a stock quote: please note that these are in USD where possible, for comparative purposes (and thus generally represent the OTC ticker).
Compass Pathways (NASDAQ: CMPS)
NASDAQ: CMPS | USD $38.89 | +10.14%
UK-based Compass Pathways are one of the most prolific players in the emergent psilocybin space, actively conducting clinical trials to demonstrate the safety of psilocybin, and its potential to tackle treatment-resistant depression.
The US Food and Drug Administration (FDA) awarded Compass a breakthrough therapy designation for their research into the use of psilocybin for severe depression. This allows the Company to accelerate the (usually very slow) development and review of their drugs. Typically, such a designation is only approved where early evidence suggests the drug in question could pose a significant improvement versus currently-available therapy.
Compass has conducted, and is conducting, a range of registered clinical trials across the world. In the United Kingdom, the Company has worked with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to successfully conduct a double-blind, placebo-controlled study with nearly ninety participants between 18-65 years of age. The study found that psilocybin was well-tolerated by the healthy adult volunteers.
Visit our Compass Pathways Company Profile to learn more.
MindMed (NEO: MMED)
OTC: MMEDF | USD $2.43 | -2.02%
MindMed is a psychedelic medicine company with a primary focus on using formulations of Ibogaine and LSD to treat mental health issues. Their current pipeline features 18-MC (derived from Ibogaine) and LSD microdosing.
The Company has a number of trials underway, on which it generally collaborates with University Hospital Basel’s Liechti Lab. These include a ‘candyflipping’ trial that seeks to understand whether combined dosing of MDMA and LSD could mitigate bad trips, as well as studies into Psilocybin.
Visit our MindMed Company Profile to learn more.
NEO: MMED | OTC: MMEDF | FWB: BGHM
Cybin Corp (NEO: CYBN)
In October 2020 Cybin announced the closing of a $45 million raise, the largest funding round for a psychedelic company in Canadian history at the time. The company went public on the NEO exchange in November 2020.
In December 2020, the company closed the acquisition of Adelia Therapeutics.
Visit our Cybin Corp Company Profile to learn more.
NEO: CYBN | OTC: CLXPF
Field Trip Health, Inc. (CSE: FTRP)
OTC: FTRPF | USD $5.75 | -2.32%
Field Trip is a mental wellness company that focuses on psychedelics and psychedelic-enhanced psychotherapy. In February 2020 they closed their Series A funding round, having raised $8.5m USD. The Company listed on the CSE on 6th Oct, 2020.
Since their CSE listing, the Company has announced an international expansion to Amsterdam, a collaboration with WHOOP, a revamped Jamaican R&D facility, and other news.
Visit our Field Trip Company Profile to learn more, including their latest news.
Revive Therapeutics Ltd. (CSE: RVV)
OTC: RVVTF | USD $0.36 | -4.08%
Revive has a primary focus on cannabinoid pharmaceuticals, but moved into the psychedelics space via the acquisition of Psilocin Pharma Corp. In December 2020, Revive announced an LOI to acquire PharmaTher’s psilocybin program, including all IP.
Unrelated to psychedelics, the company is also working on a Phase 3 study of Bucillamine for COVID-19.
Visit our Revive Therapeutics Company Profile to learn more.
CSE: RVV | OTC: RVVTF
Numinus (TSXV: NUMI)
OTC: LKYSF | USD $0.57 | -4.07%
Numinus Wellness is a publicly-traded company that is licensed (via Salvation Botanicals) by Health Canada to test, sell and distribute psychedelic substances. It listed on the TSXV exchange on Wednesday 20th May, 2020. You can read our interview with CMO Dr. Evan Wood here.
The Company’s operations include Numinus Bioscience, a testing and research facility; Numinus Health, a treatment and healing centre model; and Numinus R&D.
In October 2020, Numinus harvested their first flush of Psilocybe mushrooms, a milestone for the sector.
Visit our Numinus Company Profile to learn more.
TSXV: NUMI | OTC: LKYSF
HAVN Life Sciences (CSE: HAVN)
HAVN Life Sciences is a biotechnology company focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. They went public in September 2020.
Visit our Havn Life Company Profile to learn more.
CSE: HAVN | OTC: HAVLF
Mydecine Innovations Group (CSE: MYCO)
OTC: MYCOF | USD $0.25 | -7.84%
Mydecine Innovations Group is a publicly traded life sciences syndicate. The Company’s portfolio includes natural health products, research and development, and digital health solutions.
Visit our Mydecine Company Profile to learn more.
CSE: MYCO | OTC: MYCOF | FWB: 0NF
Red Light Holland (CSE: TRIP)
OTC: TRUFF | USD $0.17 | -6.06%
Red Light Holland is seeking to capitalise on the existing recreational market in the Netherlands, selling magic truffles via Smart Shops and an e-commerce platform.
CSE: TRIP | OTC: TRUFF
Champignon Brands Inc. (CSE: SHRM)
OTC: SHRMF | USD $0.40 | +22.15%
Mind Cure Health Inc. (CSE: MCUR)
OTC: MCURF | USD $0.24 | -2.22%
Mind Cure is exploring what it calls ‘Five Spheres’ of the sector, which includes research, discovery, clinical programs, technology, and GMP scale-up of psychedelic medicines.
The Company conducted an IPO in September 2020, and began trading publicly on the CSE on 21st September, 2020.
CSE: MCUR | OTC: MCURF
Entheon Biomedical (CSE: ENBI)
Entheon Biomedical is a biotech company focussed on the development of psychedelic medicines for addiction disorders. The Company’s research and development pipeline revolves around DMT.
The Company listed on the CSE on 12 November, 2020.
Visit our Entheon Company Profile to learn more.
CSE: ENBI | OTC: ENTBF
Better Plant Sciences (CSE: PLNT)
OTC: VEGGF | USD $0.04 | -6.28%
In August 2020 Yield Growth Corp. announced a name change to Better Plant Sciences.
The Company has a portfolio of over 100 psilocybin formulas via its subsidiary, Flourish Mushroom Labs. Flourish has formed a Company in Saint Vincent and the Grenadines, Acres Flourish Labs, which plans to construct a purpose-built laboratory for the cultivation of psilocybin mushrooms, and for R&D activities.
Flourish also acquired a founding interest in Translational Life Sciences Inc., a biotechnology company seeking to develop formulas containing restricted substances (such as cannabis and psilocybin) that may have medical applications. Flourish has already begun to file provisional US patents for their psilocybin ‘treatments’, including the administering of psilocybin/psilocin microdoses in order to encourage weight loss via the increase of metabolism and limiting of food cravings.
In December 2020, the company announced that its subsidiary NeonMind Biosciences (below) would IPO.
Visit our Better Plant Sciences Company Profile to learn more.
CSE: PLNT | OTC: VEGGF | FWB: YG3
Tryp Therapeutics (CSE: TRYP)
Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
The company has two active development programs: one exploring psilocybin for neuropsychiatric disorders, and the other is developing Razoxane for soft tissue sarcoma.
Under its Psilocybin-for-Neuropsychiatric Disorders (PFN™ ) Program, the Company is developing psilocybin-based therapeutics for neuropsychiatric indications, and plans to seek regulatory approval in-line with the FDA regulatory pathway.
Tryp intends to leverage existing third-party preclinical and clinical data to expedite their drug development programs. This is possible under the FDA’s Section 505(b)(2) pathway, which allows for the submission of New Drug Applications (NDA) that rely in part on third-party investigations.
Visit our Tryp Therapeutics Company Profile to learn more.
New Wave Holdings (CSE: SPOR)
OTC: TRMNF | USD $0.27 | -11.67%
New Wave is exploring recreational, natural (functional) and mental health applications of psychedelics. The company has two production facilities in Jamaica (via its 50% interest in Anahit International Corp.) licensed for mushroom cultivation, and is building a psilocybin-based IP portfolio.
CSE: SPOR | OTC: TRMNF | FWB: 0XM2
Aion Therapeutic (CSE: AION)
Note: in August 2020, Osoyoos Cannabis Inc. changed its name to Aion Therapeutic Inc.
Osoyoos is a company primarily associated with the cannabis space. In June 2020, the Company announced the proposed acquisition of AI Pharmaceuticals Jamaica Limited, who are engaged in the R&D of cannabis and psilocin-based pharmaceutical, nutraceutical and cosmeceutical formulations and related IP.
CSE: AION | OTC: ANTCF
Lobe Sciences (CSE: LOBE)
Lobe Sciences – formerly GreenStar Biosciences – undertook a rebrand in November 2020 to shift toward the psychedelic medicine sector. The Company acquired Eleusian Biosciences, a psychedelic medicine development company.
The Company is developing a nasal mist device to deliver psilocybin/NAC.
CSE: LOBE | OTC: GTSIF
PharmaTher (CSE: PHRM)
PharmaTher is a life sciences company focused on the R&D of psychedelics such as ketamine and psilocybin (and combinations with FDA-approved drugs) for the treatment of neurological disorders such as Parkinson’s disease, depression, and pain.
CSE: PHRM | OTCQB: PHRRF
Hollister Biosciences (CSE: HOLL)
OTC: HSTRF | USD $0.19 | -4.50%
Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space.
Visit our Hollister Biosciences Company Profile to learn more.
CSE: HOLL | OTC: HSTRF | FWB: HOB
Ehave Inc (OTC: EHVVF)
OTC: EHVVF | USD $0.02 | -2.35%
Ehave Inc provides digital therapeutics such as mental health informatics platforms. The company hopes to provide its services to the psychedelic medicine sector.
Mindset Pharma (CSE: MSET)
Mindset Pharma is a drug discovery and development company focused on developing next generation psychedelic medicines for neuropsychiatric and neurological indications with unmet needs.
CSE: MSET | OTC: MSSTF
M2BIO (OTC: WUHN)
OTC: WUHN | USD $0.38 | +8.26%
M2BIO was formerly known as Wuhan General Group, changing their name in June 2020. The company is focused on cannabis and mushroom-based sciences and also offers consumer packaged goods.
Neonmind Biosciences (CSE: NEON)
NeonMind is hoping to harness psychedelics to tackle obesity, and has filed patent applications outlining the use of psilocybin for weight loss.
CSE: NEON | FWB: 6UF
Roadman Investments Corp. (TSXV: LITT)
Roadman Investments Corp. is a Canadian Venture Capital and Advisory Firm. They have invested in a variety of companies in a range of sectors: from fintech to agriculture.
TSXV: LITT | OTC: RMANF | FWB: 1QD
PsyBio Therapeutics (TSXV: PSYB)
PsyBio Therapeutics is exploring the production of biosynthesised psilocybin and other psychoactive molecules. The process involves the use of genetically modified bacteria (such as E. coli) as part of a patent-pending process.
Bright Minds Biosciences (CSE: DRUG)
Bright Minds Biosciences is focused on the preclinical study of targeted therapies “with the potential to improve the treatment of mental health and neurological disorders.” The company intends to develop next-generation neuropsychiatric drugs through the use of serotonergic compounds.
Silo Wellness (CSE: SILO)
Silo Wellness is a psychedelics and functional mushroom company looking to develop a psilocybin nasal spray. The company also operates psilocybin retreats in Jamaica.
Filament Health is focused on the discovery and extraction of natural psychedelic drugs, in contrast to a predominant focus on synthetics and NCEs in the psychedelic space.
The company operates a manufacturing and R&D facility on the British Columbia Institute of Technology campus, and is seeking to develop an IP portfolio in a number of realms: from extraction and purification processes right through to compositions of matter for delivery methods.
Filament plans to amalgamate with a shell company, with the resulting entity to be listed on the NEO Exchange. A listing application was submitted to the NEO on April 23, 2021, and the ticker symbol FH has been reserved.
In June 2021, Filament announced a collaboration with UCSF’s TrPR Program to advance its first drug candidates through FDA Phase 1 and 2 clinical trials.
In December 2020, London-based Small Pharma received regulatory approval for a clinical trial to explore DMT for depression, which it claims is the world’s first patient clinical trial of the psychedelic. Dosing is expected to begin in January 2021 at Imperial College London’s Centre for Psychedelic Research.
On May 6, 2021, Small Pharma began trading on the TSX Venture exchange under ticker symbol DMT.
Novamind (CSE: NM)
Novamind operates a network of retreats and clinics offering ketamine-assisted therapy. It also operates a contract research organisation, Cedar Clinical Research, which conducts clinical trials for psychedelic medicine.
Awakn Life Sciences
Awakn is a psychedelics company based in the UK. They’re working across three divisions: research, clinics, and training.
In terms of clinics, Awakn hopes to open its Bristol location in Q1 2021, with London and Manchester to follow in the same year. The company is also working on clinical trials focused on MDMA, Ketamine and Psilocybin for the treatment of alcoholism and tobacco addiction.
In January 2021, Awakn appointed a CRO to conduct a study evaluating MDMA for alcohol use disorder. The Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and efficacy of MDMA as a pharmacological treatment for Alcohol Use Disorder.
There are currently two psychedelics-focused ETFs.
Defiance Next Gen Altered Experience ETF (NYSE: PSY)
The Defiance Next Gen Altered Experience ETF allows investors to gain exposure to a basket of psychedelics and cannabis stocks, trading under ticker symbol PSY on NYSE Arca; the world’s largest ETF exchange.
Importantly, its listing on the New York-based exchange provides convenient access for U.S. investors, in contrast that launched earlier this year on the Canadian NEO Exchange. At launch, 21 companies are included in the Index and thus the ETF, including Compass Pathways, MindMed, Numinus and Cybin.
Horizons Psychedelic Stock Index ETF (NEO: PSYK)
The world’s first psychedelics ETF was launched by Horizons ETFs in January 2021, marking a milestone for the space.
The ETF includes over 20 companies at present, including some larger pharmaceutical companies that have some exposure to the space, such as Johnson & Johnson which markets the esketamine product Spravato.
Private Psychedelics Companies
The following companies are active in the psychedelic space, but are not publicly traded.
ATAI Life Sciences
ATAI is a global biotechnology ‘company builder’, seeking to acquire and develop mental health treatments. With tentacles in Berlin, New York and Amsterdam, ATAI has raised large amounts of backing to finance research into psychedelic medicines for depression and other mental illnesses.
ATAI Life Sciences owns a large stake in Compass Pathways (above), after investing in their Series A round. ATAI is expected to go public in early 2021.
Visit our ATAI Life Sciences Company Profile to learn more.
The founders of Beckley Psytech hail from one of the most established think tanks / NGOs in the psychedelic medicine space: The Beckley Foundation.
The Company is building a pipeline of psychedelic compounds for a variety of mental and neurological diseases, and recently raised £14m ($18.6m) to advance the development of 5-MeO-DMT for neuropsychiatric diseases.
Visit our Beckley Psytech Company Profile to learn more.
Bexson is focused on developing novel ketamine therapies for large-market and orphan indications, including chronic pain management. Their lead project is a new, wearable ketamine delivery system that includes an infusion pump. In February 2019, the company was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome, their lead indication.
CB Therapeutics is engaged in the biosynthesis of tryptamines such as psilocybin, psilocin, and their analogs. The company claims to be the first to file intellectual property for the production of these compounds in yeast.
In December 2019, CB Therapeutics filed a US Provisional Application for a patent covering the biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi.
While this is only an application, it should be noted that CB Therapeutics has been granted patents unrelated to psychedelics in the past.
View our Psilocybin Patent Filings Tracker for further information.
Delix’s discovery platform has identified a class of non-hallucinogenic versions of psychedelic compounds, which they claim have favourable safety and therapeutic profiles. The company now plans to steward these compounds through preclinical and clinical development. Delix is keeping a relatively low profile, but its compounds have appeared in research outputs including a December 2020 article in Nature.
Diamond is looking to develop regulator-approved (FDA, EMA, Health Canada) therapies for neuropsychiatric conditions. The company is beginning with an exploration of sub-perceptual psilocybin-based medicines.
Earth Resonance provides microdosing supplements for therapeutical use. Their products are in the form of Sclerotia, which contains Psilocybin – otherwise known as magic truffles. Their products are exclusively sold in the Netherlands
Founded in 2013, Eleusis is one of the early movers in the psychedelic medicine space, with a two-pronged approach harnessing psychedelics for both anti-inflammatory and mental health applications. Learn more in our interview with Shlomi Raz, CEO and chairman.
In December 2020 the Company announced its acquisition of Kalypso Wellness Centers, a network of ketamine therapy providers in the United States.
Visit our Eleusis Company Profile to learn more.
Gilgamesh is a preclinical biotech company, seeking to develop next-generation central nervous system drugs inspired by psychedelic medicines characterised by novel benefits, improved safety profiles, and strong IP.
The company’s pipeline consists of Arylcyclohexylamine (a “Better Ketamine” for TRD and opiate use disorder); Serotonergic MicroDose (safe for home use, for ADHD, MDD); and, a Novel Ibogaine Analogue (for opioid use disorder).
MagicMed is a private Canadian company seeking to build a molecular derivatives patent library, dubbed the Psybrary™, which is initially focused on psilocybin. In September 2020 the Company closed a $1.6m private placement at $0.25 per share.
In December 2020, MagicMed closed an upsized financing of $8.1m.
Visit our MagicMed Company Profile to learn more.
MAPS Public Benefit Corporation (PBC)
MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS)
The PBC’s purpose is to focus on psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. This will primarily involve the rollout of MDMA-assisted therapy for PTSD, should it be approved.
Octarine Bio believes that its synthetic biology approach to producing psychedelic molecules will generate more consistent, pharmaceutical-grade yields at comparatively low costs.
The Company claims that the costs associated with their yeast fermentation method are at least 1,000 times lower than existing methods of psilocybin extraction.
Psilera Bioscience is seeking to harness psychedelics (including analogs) to address neurodegenerative diseases, mood disorders, and other mental health burdens.
Read our interview with Co-founder and CSO Jackie von Salm to learn more.
Psygen manufactures synthetic psychedelic drugs, which they provide to organisations conducting clinical research. The Company claims to be the first manufacturer of restricted psychedelic drug products licensed by Health Canada.
Psygen’s pilot project is licenced to manufacture psilocybin, MDMA, LSD, DMT, mescaline and 2C-B. The pilot operates at the University of Alberta under the licence of Dr. Raimar Löbenberg.
The Calgary-based company has applied to Health Canada for a corporate Dealer’s License which will allow them to manufacture, possess, sell, import, export and analyze psychedelic substances. The company is actively developing and constructing their 6000 sqft lab capable for synthesis, formulation and distribution.
California-based pharmatech startup Tactogen is focused on “developing the next generation of MDMA-like medicines.” The company describes its compounds as “gentler, less euphoric” when compared to existing psychedelics. The company suggests this may result in less need for clinical monitoring, which is a significant expense in the delivery of psychedelic therapy.
Led by neuroscientist Matthew Baggott and entrepreneur Luke Pustejovsky, Tactogen is keeping its cards close to its chest for now.
Universal Ibogaine is focused on expanding access to an ibogaine-based clinical treatment protocol for opioid addiction. The company operates Clear Sky Recovery, a clinic in Mexico that delivers Ibogaine-assisted psychotherapy for addiction.
Wake offers functional mushroom products, including various mushrooms in capsule form. The company also offers 4-6 day ‘clinical immersions’ in a diverse range of locations including Jamaica, Santa Cruz, and Brazil (coming soon).